• PLEGRIDY has demonstrated proven clinical and radiological efficacy1,2
  • PLEGRIDY has an established, manageable tolerability and safety profile1-4
  • PLEGRIDY has the lowest dosing frequency for a self-administered injectable DMT in RRMS; and patients found the autoinjector easy to use and convenient1,5-8
  • PLEGRIDY when clinically needed, may now be considered during pregnancy1
  • PLEGRIDY can be used during breast-feeding1


PLEGRIDY is indicated in adults for the treatment of relapsing remitting multiple sclerosis (RRMS).1

Biogen-51787. Date of preparation: May 2020